Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Skyrocketing Today

By Keith Speights - May 12, 2020 at 10:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another $384 million in funding for its COVID-19 vaccine program gave the biotech a big shot in the arm.

What happened

Shares of Novavax (NVAX 12.49%) are skyrocketing today, up 59.4% as of 10:30 a.m. EDT, after the biotech announced yesterday evening that the Coalition for Epidemic Preparedness Innovations (CEPI) is investing up to $384 million of additional funding in Novavax's experimental COVID-19 vaccine. In March, CEPI provided a $4 million grant to Novavax for its novel coronavirus program. 

So what

This latest investment was definitely a huge deal for Novavax. It provides a lot of money for the biotech to move forward with clinical testing of its COVID-19 vaccine candidate NVX-CoV2373. The funding also increased the perception of Novavax as a leader in the race to develop a vaccine for the novel coronavirus.

Gloved hand holding a Covid-19 vaccine syringe

Image source: Getty Images.

There's a big reason why that perception is warranted. The total $388 million for Novavax is CEPI's biggest investment ever. The organization was founded in 2017 as a partnership between the public and private sectors to fight epidemics. CEPI has funded research and development for other viruses in the past, including Ebola, Lassa, and MERS. It has established nine partnerships to develop vaccines for the novel coronavirus that causes COVID-19. But CEPI hasn't committed as much money to any other partner as it has to Novavax.

Novavax CEO Stanley Erck said, "For the last few months, the entire Novavax team has been working nonstop in an ongoing effort to make our vaccine a reality, and we appreciate CEPI's confidence in our technology platform and our progress." The major jump for the biotech stock today highlights how much investors are appreciating CEPI's confidence in Novavax's COVID-19 program, too.

Now what

It's too early to declare Novavax a winner in the scramble to develop a COVID-19 vaccine. However, the additional funding from CEPI will allow the biotech to move forward with a phase 1/2 clinical study of NVX-CoV2373 this month. Novavax will also be able to ramp up its manufacturing capabilities both internally and externally. The company hopes to be able to produce up to 100 million doses of its COVID-19 vaccine by the end of the year and produce over 1 billion doses in 2021.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$64.29 (12.49%) $7.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.